ArticleMultiple sclerosis journal - experimental, translational and clinical2021

The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomide.

Stanley Cohan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.